Evidence map›Paper›PMID 36267715›Full record

ArticleAnnals of translational medicine2022

Bioinformatics analysis of prognostic value and immune cell infiltration of

Fangjuan Hu, Ruqi Mei, Haiyan Zhang, Daijun Hao, Wei Li

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Serum α1-AT Levels andDiseases (Basel, Switzerland) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Fangjuan Hu *Second Department of Internal Medicine, Qingdao Center (Cancer) Hospital, Qingdao, China.
Ruqi Mei *Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), ICU, Peking University Cancer Hospital & Institute, Beijing, China.
Haiyan ZhangSecond Department of Internal Medicine, Qingdao Center (Cancer) Hospital, Qingdao, China.
Daijun HaoSecond Department of Internal Medicine, Qingdao Center (Cancer) Hospital, Qingdao, China.
Wei LiSecond Department of Internal Medicine, Qingdao Center (Cancer) Hospital, Qingdao, China.
Qingdao Center of Resource Chemistry and New Materials · CNPeking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cutaneous melanoma (CM) has a poor overall prognosis. Immune checkpoint inhibitor (ICI) therapy effectively improves overall survival in individuals with advanced melanoma, but only some patients benefit. Serpin Family A Member 1 ( Methods: The Cancer Genome Atlas (TCGA) and the gene expression omnibus (GEO) datasets were used to compare Results: Conclusions:

Indexed as

cutaneous melanoma (CM)immune cellsimmune checkpointsmethylationSerpin Family A Member 1 (SERPINA1)

Identifiers

PMID36267715
PMCPMC9577739
OpenAlexW4298176103

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.